<DOC>
	<DOCNO>NCT00323297</DOCNO>
	<brief_summary>To assess efficacy safety sildenafil add patient PAH take bosentan part background therapy .</brief_summary>
	<brief_title>Assess Efficacy Safety Sildenafil When Added Bosentan Treatment Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Subjects age 18 PAH bosentan therapy indicate accord national license Subjects mean pulmonary artery pressure &gt; 25mmHg pulmonary artery wedge pressure &lt; 15mmHg rest via right heart catheterization within 3 year prior randomization . Subjects whose baseline 6 Minute Walk Test distance &gt; 100m &lt; 450m . PAH secondary aetiology include congenital heart disease specify inclusion criterion Subjects whose 6 Minute Walk Test may limit condition PAH relate dyspnoea fatigue eg . claudication vascular insufficiency arthritis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>